CL2020002342A1 - Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada - Google Patents

Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada

Info

Publication number
CL2020002342A1
CL2020002342A1 CL2020002342A CL2020002342A CL2020002342A1 CL 2020002342 A1 CL2020002342 A1 CL 2020002342A1 CL 2020002342 A CL2020002342 A CL 2020002342A CL 2020002342 A CL2020002342 A CL 2020002342A CL 2020002342 A1 CL2020002342 A1 CL 2020002342A1
Authority
CL
Chile
Prior art keywords
treatment
antibodies
pustular psoriasis
generalized pustular
generalized
Prior art date
Application number
CL2020002342A
Other languages
English (en)
Inventor
Janine Lamar
Steven John Padula
Christian Thoma
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020002342A1 publication Critical patent/CL2020002342A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere al tratamiento de o el alivio de los signos y síntomas de un brote en fase aguda de la psoriasis pustulosa generalizada (GPP) con anticuerpos anti-IL36R.
CL2020002342A 2018-03-14 2020-09-10 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada CL2020002342A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US201862729518P 2018-09-11 2018-09-11

Publications (1)

Publication Number Publication Date
CL2020002342A1 true CL2020002342A1 (es) 2020-12-18

Family

ID=65904556

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002342A CL2020002342A1 (es) 2018-03-14 2020-09-10 Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada

Country Status (13)

Country Link
US (2) US20190284285A1 (es)
EP (1) EP3765513A1 (es)
JP (2) JP7404256B2 (es)
KR (1) KR102768040B1 (es)
CN (1) CN112272674A (es)
AU (1) AU2019236105B2 (es)
BR (1) BR112020016738A2 (es)
CA (1) CA3093692A1 (es)
CL (1) CL2020002342A1 (es)
IL (1) IL277215B2 (es)
MX (1) MX2020009544A (es)
PH (1) PH12020551444A1 (es)
WO (1) WO2019177888A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3283110T3 (pl) 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
WO2019177888A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
AU2019416727A1 (en) * 2018-12-27 2021-07-22 Boehringer Ingelheim International Gmbh Anti-il-36R antibodies for treatment of palmoplantar pustulosis
KR20210137520A (ko) 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
JP7812364B2 (ja) * 2020-07-17 2026-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
WO2022026832A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
CN112180007B (zh) * 2020-09-16 2023-08-18 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
CA3192882A1 (en) * 2020-09-30 2022-04-07 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
EP4301409A1 (en) * 2021-03-04 2024-01-10 Boehringer Ingelheim International GmbH Methods for the treatment of gpp
WO2022192531A2 (en) * 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CN117615788A (zh) * 2021-05-12 2024-02-27 安奈普泰斯生物有限公司 抗体组合物
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
DK0999853T3 (da) 1997-06-13 2003-04-22 Genentech Inc Stabiliseret antostofformulering
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
ATE523593T1 (de) 1997-08-01 2011-09-15 Schering Corp Membranproteine aus säugetierzellen und verwandte reagentien
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
WO2004031362A2 (en) 2002-10-03 2004-04-15 Large Scale Biology Corporation Multimeric protein engineering
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
WO2007076523A2 (en) 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
US8034771B2 (en) 2006-09-08 2011-10-11 Amgen Inc. IL-1F6 polypeptides
MX2009011500A (es) 2007-04-23 2010-01-29 Schering Corp Anticuerpos anti-mdl-1.
AU2008270710A1 (en) 2007-06-29 2009-01-08 Merck Sharp & Dohme Corp. MDL-1 uses
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
EP2212775A4 (en) 2007-10-06 2012-01-04 Fitzgerald Joan G COLLECTION OF RESEARCH DATA
RU2011105466A (ru) 2008-08-28 2012-10-10 ВАЙЕТ ЭлЭлСи (US) Применения цитокинов семейств il-22, il-17 и il-1 при аутоиммунных заболеваниях
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
PT2473528E (pt) 2009-09-03 2015-03-04 Ablynx NV Formulações estáveis de polipéptidos e seus usos
HUE039740T2 (hu) 2010-06-03 2019-01-28 Abbvie Biotechnology Ltd Alkalmazások és készítmények hidradenitis suppurativa (HS) kezelésére
FI3536710T3 (fi) * 2011-11-16 2026-01-14 Boehringer Ingelheim Int Anti-il-36r -vasta-aineita
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
US10434172B2 (en) 2013-08-15 2019-10-08 Novartis Ag Methods of treating generalized pustular psoriasis (GPP) using IL-17 antagonists
US10077434B2 (en) 2014-07-30 2018-09-18 Zumutor Biologics Inc. Non-fucosylated protein and methods thereof
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
PL3283110T3 (pl) 2015-04-15 2022-06-27 Anaptysbio, Inc. Przeciwciała skierowane przeciwko receptorowi interleukiny 36 (il-36r)
DK3285831T3 (da) 2015-04-24 2024-05-27 Shl Medical Ag Underenhed af en medikamenttilførselsanordning og en medikamenttilførselsanordning
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
WO2019177883A2 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of inflammatory bowel disease
WO2019177888A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
HRP20240999T1 (hr) 2018-07-16 2024-10-25 Regeneron Pharmaceuticals, Inc. Glodavački modeli bolesti ditra i njihova upotreba
WO2020018503A2 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Anti-il36r antibodies
AU2019416727A1 (en) 2018-12-27 2021-07-22 Boehringer Ingelheim International Gmbh Anti-il-36R antibodies for treatment of palmoplantar pustulosis
KR20210137520A (ko) 2019-03-08 2021-11-17 베링거 인겔하임 인터내셔날 게엠베하 항-il-36r 항체 제형
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
US20220402998A1 (en) 2019-10-30 2022-12-22 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
JP7812364B2 (ja) 2020-07-17 2026-02-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 好中球性皮膚症の処置のための抗ｉｌ－３６ｒ抗体
CA3192882A1 (en) 2020-09-30 2022-04-07 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain

Also Published As

Publication number Publication date
CN112272674A (zh) 2021-01-26
AU2019236105B2 (en) 2025-07-31
JP2021517566A (ja) 2021-07-26
IL277215A (en) 2020-10-29
CA3093692A1 (en) 2019-09-19
KR20200131871A (ko) 2020-11-24
KR102768040B1 (ko) 2025-02-17
EP3765513A1 (en) 2021-01-20
WO2019177888A1 (en) 2019-09-19
US12503512B2 (en) 2025-12-23
IL277215B2 (en) 2025-10-01
BR112020016738A2 (pt) 2020-12-15
JP2024028951A (ja) 2024-03-05
PH12020551444A1 (en) 2021-08-23
JP7673168B2 (ja) 2025-05-08
IL277215B1 (en) 2025-06-01
US20190284285A1 (en) 2019-09-19
MX2020009544A (es) 2020-10-05
AU2019236105A1 (en) 2020-08-27
US20210087285A1 (en) 2021-03-25
JP7404256B2 (ja) 2023-12-25

Similar Documents

Publication Publication Date Title
CL2020002342A1 (es) Uso de anticuerpos anti-il-36r para el tratamiento de la psoriasis pustulosa generalizada
CL2019002824A1 (es) Anticuerpos anti-lag3.
CL2021001179A1 (es) Anticuerpos específicos para tl1a y ácidos nucleicos que los codifican (divisional de la solicitud no. 201801596).
CL2021001685A1 (es) Anticuerpos anti-il-36r para el tratamiento de pustulosis palmoplantar
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CL2021000716A1 (es) Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269)
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2025000403A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
CL2018001790A1 (es) Procesos para preparar un inhibidor de jak1 y nuevas formas de este (divisional solicitud 201602748)
CL2021001430A1 (es) Composiciones de glp-1 y sus usos. (divisional de solicitud 202000422)
CL2021003373A1 (es) Nuevos inhibidores de egfr
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
MX2018005070A (es) Composición para el tratamiento de cáncer con expresión del igf-1r.
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
CL2021003353A1 (es) Tratamiento conjunto antineoplásico.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
CL2021003422A1 (es) Anticuerpos anti il-13ra2 y usos de los mismos (divisional 201902323).
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
CO2021000092A2 (es) Anticuerpos que comprenden un polipéptido insertado en la región 3 del marco
BR112018014355A2 (pt) processos para a preparação de f-benzoxazinorifamicina i e para a preparação de 2-amino-5-fluorobenzeno-1,3-diol iii
MX2019003569A (es) Metodos para tratar el cancer con bavituximab en funcion de niveles de b2 glucoproteina 1 y ensayos de estos.
ECSP16074207A (es) Pirazinas moduladoras de gpr6
CL2017000563A1 (es) Uso de elsiglutida para tratar mucositis gastrointestinal que incluye diarrea inducida por quimioterapia.